15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering TG Therapeutics Inc, 3 rate it Buy or better, 1 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $20.00 to $77.00 (about 3.9x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $47.40 sits 14% below the current $54.82. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.43 next quarter toward $3.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy360%
Hold120%
Sell120%
Strong Sell00%
Based on 5 analysts giving stock ratings to TG Therapeutics Inc.
As of Jul, 3 of 5 firms rate TGTX a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
TGTX EPS & revenue forecast
EPS · NEXT QUARTER
$0.43
Range $0.37 – $0.50 · 5 analysts · +170% YoY
Next period, 5 analysts expect TG Therapeutics Inc to earn $0.43 a share (range $0.37 – $0.50), versus $0.16 a year earlier. Full-year consensus is $1.61, growing to $3.28 the year after.
REVENUE · NEXT QUARTER
$244.6M
Range $237.6M – $250.4M · 5 analysts · +51% YoY
Revenue is expected to reach $244.6M (range $237.6M – $250.4M), +51.2% year-over-year. Full-year consensus is $942.4M, rising to $1.3B next year.
Top analysts covering TG Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TGTX.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$55.00+0.3% to target
Overall win rate
53%
+ Follow
#2
EW
Edward White
HC Wainwright & Co. · Rank #241
Buy
$55.00+0.3% to target
Overall win rate
31%
+ Follow
#3
Emily Bodnar
HC Wainwright & Co. · Rank #338
Buy
$77.00+40.5% to target
Overall win rate
22%
+ Follow
#4
Alec Stranahan
B of A Securities
Sell
$20.00-63.5% to target
Coverage
—
+ Follow
#5
Brian Cheng
JP Morgan
Buy
No targeton TGTX
Coverage
—
+ Follow
TGTX stock forecast FAQ
What is TGTX's average 12-month price target?+
The 5 analysts with a live target average $47.40 for TG Therapeutics Inc over the next 12 months, ranging from a $77.00 high to a $20.00 low.
Is TGTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 3 are Buy or Strong Buy, 1 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for TGTX?+
The Street-high target is $77.00 (HC Wainwright & Co.), and the Street-low is $20.00 (B of A Securities). The average of all 5 active targets is $47.40.
How many Wall Street analysts cover TGTX?+
5 analysts have an active rating on TG Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering TGTX?+
Among analysts who currently cover TGTX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $55.00 target.
What is TG Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.43 per share (range $0.37 – $0.50) across 5 analysts. Full-year EPS is projected at $1.61, rising to $3.28 the following year.
How much revenue is TG Therapeutics Inc expected to report next quarter?+
Consensus revenue is $244.6M (range $237.6M – $250.4M). Full-year revenue is projected at $942.4M, growing to $1.3B next year.
Have analysts been upgrading or downgrading TGTX lately?+
As of Jul, 3 of 5 firms rate TGTX a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TGTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
